Histological Manifestations of Abnormal Parathyroid Hormone Metabolism in Renal Osteodystrophy

2015 ◽  
pp. 1-4
Author(s):  
Steven L. Teitelbaum
Keyword(s):  
Parathyroid Hormone ◽  
Renal Osteodystrophy ◽  
Hormone Metabolism

Ethnic variations in parathyroid hormone metabolism in the morbidly obese

2005 ◽  
Vol 1 (3) ◽  
pp. 270
Author(s):  
Brandon Chock ◽  
Nahid Hamoui ◽  
Gary J. Anthone ◽  
Peter F. Crookes
Keyword(s):  
Parathyroid Hormone ◽  
Morbidly Obese ◽  
Hormone Metabolism ◽  
Ethnic Variations

scholarly journals Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy

2003 ◽  
Vol 63 (1) ◽  
pp. 1-11 ◽  
Author(s):  
William G. Goodman ◽  
Harald Jüppner ◽  
Isidro B. Salusky ◽  
Donald J. Sherrard
Keyword(s):  
Parathyroid Hormone ◽  
Renal Osteodystrophy

Pre-Operative Localisation of Parathyroid Tumours Using Neck Vein Catheterisation and Radioimmunoassay for Parathyroid Hormone: The Glasgow Experience

1983 ◽  
Vol 28 (2) ◽  
pp. 146-152 ◽  
Author(s):  
G. H. Beastall ◽  
N. McKellar ◽  
I. T. Boyle ◽  
S. N. Joffe ◽  
J. S. F. Hutchison ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Renal Osteodystrophy ◽  
Single Site ◽  
Neck Exploration ◽  
Tumour Localisation ◽  
Repeated Surgery ◽  
Parathyroid Tumour ◽  
Parathyroid Hormone Assay ◽  
Parathyroid Tumours

Reliable pre-operative localisation of parathyroid tumours can be of value in surgery for primary hyperparathyroidism, and particularly so where re-exploration of the neck is required. Neck vein catheterisation and parathyroid hormone radioimmunoassay have been suggested as a sensitive means of tumour localisation, and we report our experience of the technique over the last five years. A total of 46 patients with primary hyperparathyroidism had 50 studies performed with positive localisation and a pre-operative prediction made on 38 occasions (76%). Forty-two operations were carried out and a parathyroid tumour confirmed in 39 cases for a localisation efficiency of 69 per cent. No negative neck exploration followed a positive localisation. Twelve studies were performed in patients with renal osteodystrophy and localisation to a single site was achieved on only three occasions. It is concluded that neck vein catheterisation and parathyroid hormone assay can correctly localise parathyroid tumours in most cases of primary hyperparathyroidism, but is is suggested that its use be restricted to selected cases such as those subjects with previous negative neck exploration or patients for whom prolonged or repeated surgery may be a particular hazard.

scholarly journals Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Kittrawee Kritmetapak ◽  
Chatlert Pongchaiyakul
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Renal Osteodystrophy ◽  
Biologically Active ◽  
Intact Pth ◽  
Current Standard ◽  
Mineral And Bone Disorder ◽  
Wide Range ◽  
Serum Pth

Accurate measurement of parathyroid hormone (PTH) is crucial for therapeutic decision-making in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD). The second-generation PTH assays, often referred to as “intact PTH” assays, are the current standard and most available assays in clinical practice. However, intact PTH assays measure both full-length biologically active PTH and heterogeneous PTH fragments in the circulation, providing the equivocal value of PTH measurement in patients with CKD-MBD. Due to the variability of PTH assays, preanalytical sample errors, and the phenomenon of end-organ PTH hyporesponsiveness, current CKD-MBD guidelines recommend a wide range for serum PTH targets (2–9 the upper normal limit of the intact PTH assay) in dialysis patients to diminish the risk of developing adynamic bone disease. Nevertheless, a sizeable proportion of CKD patients still experience renal osteodystrophy despite having serum PTH levels within the recommended range. The primary cause of this inconsistency is the analytical interference of various PTH fragments and oxidized PTH forms that considerably accumulate in CKD patients. Therefore, a new mass spectrometry-based assay, which is capable of specifically measuring the whole spectra of PTH fragments, can potentially improve diagnostic accuracy for renal osteodystrophy. However, the effects of different PTH fragments on bone metabolism, vascular calcification, and mortality in CKD patients warrant further research.

Comparison of Parathyroid Hormone Assays with Bone Histomorphometry in Renal Osteodystrophy*

1986 ◽  
Vol 63 (5) ◽  
pp. 1163-1169 ◽  
Author(s):  
DENNIS L. ANDRESS ◽  
DAVID B. ENDRES ◽  
NORMA A MALONEY ◽  
JEFFREY B. KOPP ◽  
JACK W. COBURN ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Renal Osteodystrophy ◽  
Bone Histomorphometry

EFFECTS OF CIMETIDINE ON PARATHYROID HORMONE METABOLISM

The Lancet ◽  
1981 ◽  
Vol 317 (8218) ◽  
pp. 501 ◽  
Author(s):  
C.E. Fiore ◽  
L.S. Malatino ◽  
J.A. Kanis
Keyword(s):  
Parathyroid Hormone ◽  
Hormone Metabolism

Serum phosphorus adds to value of serum parathyroid hormone for assessment of bone turnover in renal osteodystrophy

2016 ◽  
Vol 86 (07) ◽  
pp. 9-17 ◽  
Author(s):  
Jimmy Gentry ◽  
Jonathan Webb ◽  
Daniel Davenport ◽  
Hartmut H. Malluche
Keyword(s):  
Parathyroid Hormone ◽  
Bone Turnover ◽  
Renal Osteodystrophy ◽  
Serum Phosphorus ◽  
Serum Parathyroid Hormone
Sign in / Sign up

Export Citation Format

Share Document